Madrigal Historical Balance Sheet

MDGL Stock

USD 312.11 9.94 3.29%

Trend analysis of Madrigal Pharmaceuticals balance sheet accounts such as Common Stock Total Equity of 4.3 K provides information on Madrigal Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Madrigal Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Madrigal Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Madrigal Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Madrigal Pharmaceuticals is a good buy for the upcoming year.

Madrigal Pharmaceuticals Inventory

35.77 Million

Build AI portfolio with Madrigal Stock

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

About Madrigal Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Madrigal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Madrigal Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Madrigal Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Madrigal currently owns. An asset can also be divided into two categories, current and non-current.

Madrigal Pharmaceuticals Balance Sheet Chart

At this time, Madrigal Pharmaceuticals' Other Stockholder Equity is quite stable compared to the past year. Total Liabilities is expected to rise to about 302.3 M this year, although the value of Retained Earnings are projected to rise to (1.7 B).

Total Assets Total Stockholder Equity Common Stock Total Equity Common Stock Shares Outstanding

Add Fundamental

Total Assets

Total assets refers to the total amount of Madrigal Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Madrigal Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Madrigal Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' Other Stockholder Equity is quite stable compared to the past year. Total Liabilities is expected to rise to about 302.3 M this year, although the value of Retained Earnings are projected to rise to (1.7 B).

	2022	2023	2024	2025 (projected)
Total Stockholder Equity	197.4M	405.3M	754.4M	792.1M
Total Assets	362.6M	640.5M	1.0B	1.1B

Total Stockholder Equity Total Assets

Madrigal Pharmaceuticals balance sheet Correlations

	Total Assets	Total Stockholder Equity	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Short Term Investments	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Long Term Debt Total	Non Current Liabilities Total	Short Term Debt	Net Receivables
Total Assets		0.98	-0.3	0.85	0.94	0.89	-0.37	0.88	0.86	0.74	-0.27	0.06	-0.81	0.87	0.24	0.81	0.41	1.0	0.97	0.91	0.74	1.0	0.84	0.86	-0.3	0.79
Total Stockholder Equity	0.98		-0.33	0.85	0.87	0.78	-0.4	0.78	0.75	0.67	-0.28	-0.03	-0.7	0.77	0.3	0.75	0.39	0.98	0.97	0.88	0.67	0.98	0.74	0.76	-0.32	0.75
Common Stock Total Equity	-0.3	-0.33		-0.57	-0.19	-0.18	1.0	-0.27	-0.1	-0.23	-0.2	0.25	-0.09	-0.21	-0.3	-0.11	-0.25	-0.34	-0.29	-0.17	-0.23	-0.35	-0.11	-0.17	0.83	-0.13
Common Stock Shares Outstanding	0.85	0.85	-0.57		0.77	0.72	-0.61	0.81	0.72	0.5	-0.38	-0.14	-0.59	0.72	0.37	0.49	0.53	0.87	0.79	0.65	0.5	0.86	0.61	0.64	-0.49	0.47
Other Stockholder Equity	0.94	0.87	-0.19	0.77		0.97	-0.26	0.95	0.93	0.8	-0.28	0.22	-0.92	0.95	0.1	0.86	0.43	0.93	0.88	0.9	0.8	0.94	0.93	0.93	-0.31	0.79
Total Liab	0.89	0.78	-0.18	0.72	0.97		-0.24	0.97	0.97	0.8	-0.22	0.28	-0.96	0.97	0.06	0.83	0.39	0.88	0.8	0.85	0.8	0.88	0.97	0.97	-0.22	0.75
Common Stock	-0.37	-0.4	1.0	-0.61	-0.26	-0.24		-0.33	-0.16	-0.28	-0.19	0.22	-0.03	-0.27	-0.3	-0.18	-0.25	-0.4	-0.35	-0.24	-0.28	-0.41	-0.17	-0.23	0.84	-0.21
Other Current Liab	0.88	0.78	-0.27	0.81	0.95	0.97	-0.33		0.97	0.77	-0.23	0.22	-0.91	0.96	0.09	0.79	0.48	0.87	0.78	0.83	0.77	0.88	0.89	0.9	-0.31	0.72
Total Current Liabilities	0.86	0.75	-0.1	0.72	0.93	0.97	-0.16	0.97		0.75	-0.26	0.27	-0.97	0.96	0.05	0.79	0.39	0.84	0.76	0.83	0.75	0.84	0.9	0.91	-0.1	0.73
Property Plant And Equipment Net	0.74	0.67	-0.23	0.5	0.8	0.8	-0.28	0.77	0.75		0.27	0.5	-0.75	0.78	-0.24	0.93	0.39	0.75	0.76	0.79	1.0	0.77	0.8	0.81	-0.29	0.83
Current Deferred Revenue	-0.27	-0.28	-0.2	-0.38	-0.28	-0.22	-0.19	-0.23	-0.26	0.27		0.11	0.28	-0.2	-0.18	0.08	-0.31	-0.23	-0.2	-0.13	0.27	-0.22	-0.17	-0.16	-0.11	0.12
Net Debt	0.06	-0.03	0.25	-0.14	0.22	0.28	0.22	0.22	0.27	0.5	0.11		-0.36	0.24	-0.94	0.45	0.2	0.03	0.14	0.23	0.5	0.06	0.31	0.29	0.16	0.31
Retained Earnings	-0.81	-0.7	-0.09	-0.59	-0.92	-0.96	-0.03	-0.91	-0.97	-0.75	0.28	-0.36		-0.93	0.04	-0.81	-0.33	-0.79	-0.73	-0.81	-0.75	-0.79	-0.93	-0.92	-0.01	-0.73
Accounts Payable	0.87	0.77	-0.21	0.72	0.95	0.97	-0.27	0.96	0.96	0.78	-0.2	0.24	-0.93		0.08	0.83	0.31	0.86	0.79	0.87	0.78	0.87	0.91	0.92	-0.26	0.78
Cash	0.24	0.3	-0.3	0.37	0.1	0.06	-0.3	0.09	0.05	-0.24	-0.18	-0.94	0.04	0.08		-0.17	-0.09	0.27	0.14	0.05	-0.24	0.25	0.03	0.05	-0.23	-0.06
Non Current Assets Total	0.81	0.75	-0.11	0.49	0.86	0.83	-0.18	0.79	0.79	0.93	0.08	0.45	-0.81	0.83	-0.17		0.31	0.79	0.8	0.93	0.93	0.82	0.83	0.82	-0.21	0.95
Non Currrent Assets Other	0.41	0.39	-0.25	0.53	0.43	0.39	-0.25	0.48	0.39	0.39	-0.31	0.2	-0.33	0.31	-0.09	0.31		0.42	0.38	0.23	0.39	0.41	0.31	0.31	-0.34	0.1
Cash And Short Term Investments	1.0	0.98	-0.34	0.87	0.93	0.88	-0.4	0.87	0.84	0.75	-0.23	0.03	-0.79	0.86	0.27	0.79	0.42		0.97	0.88	0.75	1.0	0.83	0.85	-0.33	0.77
Short Term Investments	0.97	0.97	-0.29	0.79	0.88	0.8	-0.35	0.78	0.76	0.76	-0.2	0.14	-0.73	0.79	0.14	0.8	0.38	0.97		0.88	0.76	0.97	0.78	0.8	-0.29	0.78
Other Current Assets	0.91	0.88	-0.17	0.65	0.9	0.85	-0.24	0.83	0.83	0.79	-0.13	0.23	-0.81	0.87	0.05	0.93	0.23	0.88	0.88		0.79	0.91	0.81	0.81	-0.22	0.96
Property Plant And Equipment Gross	0.74	0.67	-0.23	0.5	0.8	0.8	-0.28	0.77	0.75	1.0	0.27	0.5	-0.75	0.78	-0.24	0.93	0.39	0.75	0.76	0.79		0.77	0.8	0.81	-0.29	0.83
Total Current Assets	1.0	0.98	-0.35	0.86	0.94	0.88	-0.41	0.88	0.84	0.77	-0.22	0.06	-0.79	0.87	0.25	0.82	0.41	1.0	0.97	0.91	0.77		0.84	0.86	-0.36	0.8
Short Long Term Debt Total	0.84	0.74	-0.11	0.61	0.93	0.97	-0.17	0.89	0.9	0.8	-0.17	0.31	-0.93	0.91	0.03	0.83	0.31	0.83	0.78	0.81	0.8	0.84		1.0	-0.18	0.74
Non Current Liabilities Total	0.86	0.76	-0.17	0.64	0.93	0.97	-0.23	0.9	0.91	0.81	-0.16	0.29	-0.92	0.92	0.05	0.82	0.31	0.85	0.8	0.81	0.81	0.86	1.0		-0.21	0.74
Short Term Debt	-0.3	-0.32	0.83	-0.49	-0.31	-0.22	0.84	-0.31	-0.1	-0.29	-0.11	0.16	-0.01	-0.26	-0.23	-0.21	-0.34	-0.33	-0.29	-0.22	-0.29	-0.36	-0.18	-0.21		-0.16
Net Receivables	0.79	0.75	-0.13	0.47	0.79	0.75	-0.21	0.72	0.73	0.83	0.12	0.31	-0.73	0.78	-0.06	0.95	0.1	0.77	0.78	0.96	0.83	0.8	0.74	0.74	-0.16

Click cells to compare fundamentals

Madrigal Pharmaceuticals Account Relationship Matchups

Madrigal Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	287.0M	273.3M	362.6M	640.5M	1.0B	1.1B
Total Stockholder Equity	240.0M	196.1M	197.4M	405.3M	754.4M	792.1M
Common Stock Shares Outstanding	15.4M	16.5M	17.1M	18.7M	21.3M	22.3M
Liabilities And Stockholders Equity	287.0M	273.3M	362.6M	640.5M	1.0B	1.1B
Other Stockholder Equity	665.4M	863.5M	1.2B	1.7B	2.6B	2.7B
Total Liab	47.0M	77.2M	165.2M	235.2M	287.9M	302.3M
Other Current Liab	45.2M	55.0M	91.5M	90.0M	124.7M	130.9M
Total Current Liabilities	46.6M	76.8M	115.9M	118.5M	169.3M	177.7M
Property Plant And Equipment Net	1.8M	1.6M	1.2M	3.3M	4.6M	4.8M
Net Debt	(53.2M)	(35.5M)	(281.7M)	17.3M	19.6M	20.5M
Retained Earnings	(425.5M)	(667.3M)	(962.7M)	(1.3B)	(1.8B)	(1.7B)
Accounts Payable	1.0M	21.4M	23.8M	28.0M	43.6M	45.8M
Cash	54.0M	36.3M	331.5M	99.9M	100.0M	100.2M
Non Current Assets Total	1.8M	1.6M	1.2M	3.3M	9.3M	9.8M
Non Currrent Assets Other	1.9M	1.8M	797K	1.2M	1.4M	719.9K
Cash And Short Term Investments	284.1M	270.3M	358.8M	634.1M	926.3M	972.6M
Short Term Investments	230.1M	234.1M	27.2M	534.2M	826.2M	867.5M
Other Current Assets	2.0M	2.7M	2.6M	3.2M	18.8M	19.7M
Property Plant And Equipment Gross	1.8M	1.6M	1.2M	3.3M	4.6M	4.8M
Total Current Assets	285.2M	271.7M	361.4M	637.3M	1.0B	1.1B
Accumulated Other Comprehensive Income	47K	(80K)	(32K)	468K	538.2K	565.1K
Short Long Term Debt Total	786K	797K	49.9M	117.2M	119.6M	125.5M
Non Current Liabilities Total	468K	387K	49.3M	116.7M	118.6M	124.5M
Short Term Debt	318K	410K	602K	527K	983K	933.9K
Net Tangible Assets	416.6M	240.0M	196.1M	197.4M	227.0M	184.4M
Retained Earnings Total Equity	(223.2M)	(425.5M)	(667.3M)	(962.7M)	(866.4M)	(823.1M)
Capital Surpluse	639.6M	665.4M	863.5M	1.2B	1.3B	1.4B
Capital Lease Obligations	786K	797K	602K	1.7M	2.0M	2.1M
Property Plant Equipment	1.2M	1.0M	1.6M	601K	691.2K	734.4K
Net Invested Capital	240.0M	196.1M	246.7M	520.8M	872.0M	915.5M
Net Working Capital	238.6M	194.8M	245.5M	518.7M	863.7M	906.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:

How To Invest In Madrigal

Details

Is Madrigal Stock a good investment?

Details

What is Madrigal Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(18.41)

Revenue Per Share

14.562

Return On Assets

(0.26)

Return On Equity

(0.50)

The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Madrigal Historical Balance Sheet

Madrigal Pharmaceuticals Inventory

35.77 Million

About Madrigal Balance Sheet Analysis

Madrigal Pharmaceuticals Balance Sheet Chart

Total Assets

Total Stockholder Equity

Common Stock Total Equity

Common Stock Shares Outstanding

Madrigal Pharmaceuticals balance sheet Correlations

Madrigal Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Madrigal Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	Total Stockholder Equity
Other Assets	Common Stock Total Equity
Common Stock Shares Outstanding	Liabilities And Stockholders Equity
Other Stockholder Equity	Total Liab
Common Stock	Other Current Liab
Total Current Liabilities	Property Plant And Equipment Net
Current Deferred Revenue	Net Debt
Retained Earnings	Accounts Payable
Cash	Non Current Assets Total
Non Currrent Assets Other	Cash And Short Term Investments
Short Term Investments	Other Current Assets
Property Plant And Equipment Gross	Total Current Assets
Accumulated Other Comprehensive Income	Short Long Term Debt Total
Non Current Liabilities Total	Short Term Debt
Net Receivables	Net Tangible Assets
Total Permanent Equity	Noncontrolling Interest In Consolidated Entity
Long Term Debt	Good Will
Retained Earnings Total Equity	Long Term Debt Total
Capital Surpluse	Capital Lease Obligations
Inventory	Additional Paid In Capital
Deferred Long Term Liab	Preferred Stock Total Equity
Treasury Stock	Intangible Assets
Temporary Equity Redeemable Noncontrolling Interests	Property Plant Equipment
Short Long Term Debt	Net Invested Capital
Net Working Capital	Capital Stock
Non Current Liabilities Other

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total

Retained Earnings	- 0.97	Total Current Liabilities
Retained Earnings	- 0.96	Total Liab
Cash	- 0.94	Net Debt
Short Long Term Debt Total	- 0.93	Retained Earnings
Accounts Payable	- 0.93	Retained Earnings
Non Current Liabilities Total	- 0.92	Retained Earnings